The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지
DOI QR코드

DOI QR Code

Current Status of N-of-1 Trials for Herbal Medicine -Literature Review

한약에 대한 N-of-1 임상시험의 현황 - 문헌 고찰

  • Received : 2020.01.16
  • Accepted : 2020.02.28
  • Published : 2020.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: To overcome the limitations of randomized controlled trials, many other trials design is tested. The n-of-1 trial is a promising research method in the field of Korean medicine because of this methodology can examine the optimal treatment for each patient strictly. Therefore, we reviewed the status of N-of-1 studies on herbal medicine. Methods: A systematic literature review was conducted based on the pubmed database. The search term were 'N-of-1 Trial', 'Chinese Medicine', 'Herbal Medicine', 'Kampo'. There was no restriction in year. Results: Four clinical trials have been identified to demonstrate the effectiveness of herbal medicines for Kidney-yin-deficiency syndrome, bronchiectasis and gastric cancer. These studies suggest that the N-of-1 design is a study that encourages patient involvement, demonstrates the effectiveness of herbal medicines and helps reduce unnecessary medication. Conclusion: The N-of-1 clinical trial may be a rigorous methodology suitable for the clinical setting and may help the development of evidence-based Korean medicine. Attention is also needed in this research method in Korea.

Keywords

References

  1. Akobeng AK. Understanding randomised controlled trials. Archives of Disease in Childhood. 2005; 90: 8. 840-844. https://doi.org/10.1136/adc.2004.058222
  2. Spieth PM, Kubasch AS, Penzlin AI, Illigens BM, Barlinn K, Siepmann T., Randomized controlled trials - a matter of design., Neuropsychiatric Disease and Treatment. 2016;12. 1341-9.
  3. Suresh K. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. Journal of Human Reproductive Sciences. 2011; 4: 1. 8-11. https://doi.org/10.4103/0974-1208.82352
  4. Jones DS, Podolsky SH. The history and fate of the gold standard. Lancet. 2015; 385: 9977.1502-3. https://doi.org/10.1016/S0140-6736(15)60742-5
  5. Chao J, Dai Y, Verpoorte R, Lam W, Cheng YC, Pao LH, et al. Major achievements of evidence-based traditional Chinese medicine in treating major diseases. Biochemical Pharmacology. 2017; 139. 94-104. https://doi.org/10.1016/j.bcp.2017.06.123
  6. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312: 7023. 71-2. https://doi.org/10.1136/bmj.312.7023.71
  7. Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy--randomized trials in individual patients. The New England Journal of Medicine. 1986;314: 14.889-92. https://doi.org/10.1056/NEJM198604033141406
  8. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT., The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Annals of Internal Medicine. 1990; 112 : 4. 293-9. https://doi.org/10.7326/0003-4819-112-4-293
  9. Shaffer JA, Kronish IM, Falzon L, Cheung YK, Davidson KW. N-of-1 Randomized Intervention Trials in Health Psychology: A Systematic Review and Methodology Critique. Annals of Behavioral Medicine. 2018; 52: 9. 731-742. https://doi.org/10.1093/abm/kax026
  10. Mirza RD, Punja S, Vohra S, Guyatt G. The history and development of N-of-1 trials. Journal of the Royal Society of Medicine. 2017; 110 : 8. 330-340. https://doi.org/10.1177/0141076817721131
  11. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Personalized Medicine. 2011; 8: 2. 161-173. https://doi.org/10.2217/pme.11.7
  12. Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015; 520: 7549.609-11. https://doi.org/10.1038/520609a
  13. Terasawa K. Evidence-based Reconstruction of Kampo Medicine: Part-III-How Should Kampo be Evaluated? Evidence-Based Complementary and Alternative Medicine. 2004; 1 :3. 219-222. https://doi.org/10.1093/ecam/neh046
  14. Li J, Tian J, Ma B, Yang K. N-of-1 trials in China. Complementary Therapies in Medicine. 2013; 21: 3. 190-4. https://doi.org/10.1016/j.ctim.2013.01.003
  15. Yoshinaga R, Goto Y, Inoue H, Yano H, Nabeshima S, Tahara E. A Case of Lower Back with Extremity Pain Successfully Treated with Kanzobushito. Kampo Medicine. 2019;70: 2. 146-150. https://doi.org/10.3937/kampomed.70.146
  16. Tsubo T, Unita A, Furuta T, Suzuki M, Ueno T, Suzuki T, et al. A Patient with Diffuse Panbronchiolitis Treated with a Combination of Keishikyoshakuyakukasokyoto and Acupuncture. Kampo Medicine 2019; 70: 2. 99-105. https://doi.org/10.3937/kampomed.70.99
  17. Jeung CW, Jeon SW, Kim HK. Reduction of Adverse Effects from Jayeumganghwa-tang for Pegylated Liposomal Doxorubicin and Carboplatin in Recurrent Ovarian Cancer. The Journal of Internal Korean Medicine. 2019; 40: 6. 1278-1287. https://doi.org/10.22246/jikm.2019.40.6.1278
  18. Yuhong H, Qian L, Yu L, Yingqiang Z, Yanfen L, Shujing Y, et al. An n-of-1 Trial Service in Clinical Practice: Testing the Effectiveness of Liuwei Dihuang Decoction for Kidney-Yin Deficiency Syndrome. Evidence -Based Complementary and Alternative Medicine. 2013; 2013. 827915. https://doi.org/10.1155/2013/827915
  19. Huang H, Yang P, Xue J, Tang J, Ding L, Ma Y, et al. Evaluating the Individualized Treatment of Traditional Chinese Medicine: A Pilot Study of N-of-1 Trials. Evidence-Based Complementary and Alternative Medicine. 2014; 2014. 148730.
  20. Huang H, Yang P, Wang J, Wu Y, Zi S, Tang J, et al. Investigation into the Individualized Treatment of Traditional Chinese Medicine through a Series of N-of-1 Trials. Evidence-Based Complementary and Alternative Medicine. 2018; 2018. 5813767. https://doi.org/10.1155/2018/5813767
  21. Li J, Niu J, Yang M, Ye P, Zhai J, Yuan W, et al. Using single-patient (n-of-1) trials to determine effectiveness of traditional Chinese medicine on chemotherapy-induced leukopenia in gastric cancer: a feasibility study. Annals of Translational Medicine. 2019; 7: 6. 124. https://doi.org/10.21037/atm.2019.02.03
  22. Li J, Wei D, Niu J, Yang M, Ge L, Wang X, et al. Potential Facilitators and Barriers to Awareness of N-of-1 Trials for Physicians in Traditional Chinese Medicine. Alternative Therapies In Health And Medicine. 2018; 24:2. 44-49.
  23. Xie T, Yu Z. N-of-1 Design and Its Applications to Personalized Treatment Studies. Statistics in Biosciences. 2017; 9: 2. 662-675. https://doi.org/10.1007/s12561-016-9165-9
  24. Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, et al. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM) : Recommendations, explanation and elaboration. Complementary Therapies in Medicine. 2019; 46. 180-188. https://doi.org/10.1016/j.ctim.2019.08.014
  25. Chen J, Huang J, Li JV, Lv Y, He Y, Zheng Q. The Characteristics of TCM Clinical Trials: A Systematic Review of ClinicalTrials.gov. Evidence-Based Complementary and Alternative Medicine. 2017; 2017. 9461415
  26. Kravitz RL, Schmid CH, Marois M, Wilsey B, Ward D, Hays RD, et al. Effect of Mobile Device-Supported Single-Patient Multi-crossover Trials on Treatment of Chronic Musculoskeletal Pain: A Randomized Clinical Trial. JAMA Internal Medicine. 2018; 178: 10. 1368-1377. https://doi.org/10.1001/jamainternmed.2018.3981
  27. Mirza RD, Guyatt GH. A Randomized Clinical Trial of n-of-1 Trials-Tribulations of a Trial. JAMA Internal Medicine. 2018; 178: 10. 1378-1379. https://doi.org/10.1001/jamainternmed.2018.3979
  28. Kravitz RL, Sim I, Duan N. A Case for n-of-1 Trials-Reply. JAMA Internal Medicine. 2019; 179: 3. 453. https://doi.org/10.1001/jamainternmed.2018.7180
  29. Terasawa K. Evidence-based Reconstruction of Kampo Medicine: Part II-The Concept of Sho. Evidence-Based Complementary and Alternative Medicine. 2004; 1: 2. 119-123. https://doi.org/10.1093/ecam/neh022
  30. Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. Journal of Clinical Epidemiology. 2013; 66: 8 Suppl. S21-8. https://doi.org/10.1016/j.jclinepi.2013.04.006
  31. Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. Journal of Clinical Epidemiology 2010; 63: 12. 1312-1323. https://doi.org/10.1016/j.jclinepi.2010.04.020
  32. Takahashi K, Yoshino T, Maki Y, Ishiuchi K, Namiki T, Ogawa-Ochiai K, et al. Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: a multi-centre cross-sectional study. Archives of Toxicology. 2019; 93: 11. 3111-3119. https://doi.org/10.1007/s00204-019-02588-2
  33. Sanchez-Vidana DI, Rajwani R, Wong MS. The Use of Omic Technologies Applied to Traditional Chinese Medicine Research. Evidence-Based Complementary and Alternative Medicine. 2017; 2017. 6359730.